GB2596491B - Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients - Google Patents
Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients Download PDFInfo
- Publication number
- GB2596491B GB2596491B GB2114517.2A GB202114517A GB2596491B GB 2596491 B GB2596491 B GB 2596491B GB 202114517 A GB202114517 A GB 202114517A GB 2596491 B GB2596491 B GB 2596491B
- Authority
- GB
- United Kingdom
- Prior art keywords
- fraxin
- preventing
- composition
- active ingredients
- attention deficit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2114517.2A GB2596491B (en) | 2018-12-18 | 2018-12-18 | Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2109624.3A GB2596927B (en) | 2018-12-18 | 2018-12-18 | Composition for preventing or treating dementia and improving cognitive ability |
| GB2114517.2A GB2596491B (en) | 2018-12-18 | 2018-12-18 | Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB202114517D0 GB202114517D0 (en) | 2021-11-24 |
| GB2596491A GB2596491A (en) | 2021-12-29 |
| GB2596491B true GB2596491B (en) | 2022-06-29 |
Family
ID=78595557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2114517.2A Active GB2596491B (en) | 2018-12-18 | 2018-12-18 | Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2596491B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001049281A2 (en) * | 1999-12-30 | 2001-07-12 | Proteotech, Inc. | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES |
| KR20110110638A (en) * | 2010-04-01 | 2011-10-07 | 김현기 | Cognitive Improving Composition Comprising Ginseng Extract as Active Ingredient |
| WO2019109300A1 (en) * | 2017-12-07 | 2019-06-13 | Guochuan Emil Tsai | Improved enrichment methods for preparing tannic acid compositions |
| WO2019225983A1 (en) * | 2018-05-25 | 2019-11-28 | 한국 한의학 연구원 | Composition for preventing, ameliorating, or treating depression and anxiety disorders, comprising fraxin as active ingredient |
| TWI686192B (en) * | 2017-02-13 | 2020-03-01 | 心悅生醫股份有限公司 | Compositions containing tannic acids and uses thereof |
-
2018
- 2018-12-18 GB GB2114517.2A patent/GB2596491B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001049281A2 (en) * | 1999-12-30 | 2001-07-12 | Proteotech, Inc. | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES |
| KR20110110638A (en) * | 2010-04-01 | 2011-10-07 | 김현기 | Cognitive Improving Composition Comprising Ginseng Extract as Active Ingredient |
| TWI686192B (en) * | 2017-02-13 | 2020-03-01 | 心悅生醫股份有限公司 | Compositions containing tannic acids and uses thereof |
| WO2019109300A1 (en) * | 2017-12-07 | 2019-06-13 | Guochuan Emil Tsai | Improved enrichment methods for preparing tannic acid compositions |
| WO2019225983A1 (en) * | 2018-05-25 | 2019-11-28 | 한국 한의학 연구원 | Composition for preventing, ameliorating, or treating depression and anxiety disorders, comprising fraxin as active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2596491A (en) | 2021-12-29 |
| GB202114517D0 (en) | 2021-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202011357RA (en) | Compounds for promoting hair growth and/or inhibiting or delaying hair loss in humans, and compositions for such uses | |
| EP3354257A4 (en) | Composition, for improving skin and preventing hair loss, comprising plant extract-derived extracellular vesicles | |
| EP3630058A4 (en) | Compositions and methods for preventing, slowing, and reversing skin aging | |
| TW201613867A (en) | Difluoromethyl-nicotinic-indanyl carboxamides | |
| MX2018000075A (en) | Microbiome-compatible cosmetics. | |
| EP3357501A4 (en) | Composition for preventing hair loss or promoting hair growth, containing ginseng-derived exosome-like vesicles | |
| EP3020405A4 (en) | Composition for preventing and treating liver fibrosis or liver cirrhosis,containing, as active ingredient, mesenchymal stem cells derived from human embryonic stem cells | |
| MX2017011309A (en) | Hair conditioning compositions with microcapsules. | |
| EP3111918A4 (en) | Skin cosmetic composition, antibacterial agent for skin cosmetic, and method for enhancing antibacterial effect of diol compound | |
| EP3199174A4 (en) | Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia, and composition thereof | |
| EP3187579A4 (en) | Composition, support, wastewater treatment system, wastewater treating method, deodorization method, and batch wastewater treating method | |
| IL271134B1 (en) | Composition and its uses for flavoring or perfuming | |
| ZA202001921B (en) | Pharmaceuticals composition for treating keloid and uses thereof | |
| EP3040078A4 (en) | Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent | |
| MX2017010841A (en) | Enhanced perfume compositions. | |
| EP3442497B8 (en) | Active combinations, compositions and methods for enhancing hair growth | |
| EP3347009A4 (en) | Composition comprising resveratrol and melatonin for reducing hair loss and/or increasing hair regrowth | |
| SG10202007780YA (en) | Tin-containing dopant compositions, systems and methods for use in ion implantation systems | |
| EP3662914A4 (en) | Composition for preventing or treating scars | |
| IL268224A (en) | Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients | |
| HUE055326T2 (en) | Compositions for use in treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine | |
| BR112017023316A2 (en) | cosmetic method and therapeutic use for fat reduction | |
| EP3900732C0 (en) | Composition for improving cognitive ability and preventing or treating dementia and attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients | |
| EP3144005A4 (en) | Composition for preventing and treating male infertility, containing mixed herbal extract as active ingredient and use thereof | |
| GB2596491B (en) | Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients |